TRV 027

Drug Profile

TRV 027

Alternative Names: Beta-arrestin biased ligand - Trevena; MPS-418; TRV-120027; TRV027; β-arrestin biased ligand - Trevena

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trevena
  • Class Heart failure therapies; Oligopeptides; Vasodilators
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Beta-arrestin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute heart failure

Most Recent Events

  • 15 Apr 2016 Trevena completes enrolment in a phase II trial for Acute heart failure (NCT01966601)
  • 04 Dec 2015 Trevena has patent protection for TRV 027 in Europe
  • 30 Jun 2015 TRV 027 is still in phase II trials for Acute heart failure (Combination therapy, First-line therapy) in USA, Argentina, Bulgaria, Canada, Czech Republic, Hungary, Germany, Israel, Poland, Romania, Russia and Slovakia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top